# Ventriculair hartritme en hartfalen versterken elkaar wederzijds bij ICD-patiënten na infarct

*geplaatst 2026-11-14 · Hartfalen · European journal of heart failure · doi 10.1093/ejhf/xuag312 · https://hartvaat.nl/2026/11/06/ventriculair-hartritme-en-hartfalen-versterken-elkaar-wederzijds-bij-icd-patient/*

In een multicentre cohort van 1014 patiënten met een uitgesproken linkerventrikel-disfunctie na een myocardinfarct en een geïmplanteerde defibrillator, bleek dat ventriculaire hartritmestoornissen (VA) en hartfalen-episoden elkaar wederzijds versterken. VA verhoogde het risico op hartfalen-episoden met een aHR van 3,50, terwijl hartfalen het risico op latere VA met een aHR van 2,96 verhoogde; beide waren onafhankelijk geassocieerd met een verhoogd sterftecijfer. Deze wederzijdse interactie benadrukt de noodzaak van een geïntegreerde aanpak van hartritmestoornissen en hartfalen bij de follow-up van deze risicopatiënten.

## English: Ventricular arrhythmia-heart failure interaction and mortality in ICD recipients after myocardial infarction.

In a multicentre cohort of 1,014 patients with persistent left ventricular dysfunction following myocardial infarction and an implanted cardioverter-defibrillator (ICD), ventricular arrhythmias (VA) and heart failure events demonstrated a strong bidirectional relationship. VA independently increased the risk of subsequent heart failure events (aHR 3.50), while heart failure episodes raised the risk of later VA (aHR 2.96), with both conditions independently linked to higher all-cause mortality. These findings underscore the clinical importance of integrated management strategies for arrhythmias and heart failure in post-infarction patients with reduced ejection fraction.

## Abstract (original, from the publication)

AIMS: Ventricular arrhythmia (VA) and heart failure (HF) frequently coexist in patients with ischaemic left ventricular (LV) dysfunction. Whether VA and HF events are bidirectionally associated remains unclear. We investigated their bidirectional relationship and associations with mortality. METHODS: We analysed 1014 patients from the multicentre WICD-MI study. All received a wearable cardioverter-defibrillator after acute myocardial infarction (MI) and subsequently underwent implantable cardioverter-defibrillator (ICD) implantation, with persistent LV ejection fraction ≤35%. Associations between ICD-treated VA, HF-events (HF hospitalization, heart transplantation, or LV assist device implantation), and all-cause mortality were assessed using time-dependent Cox models. RESULTS: Over a median follow-up of 2.6 years post-ICD implantation, VA was independently associated with an increased risk of HF events [aHR = 3.50 (1.66-7.38), P = .001], while HF events similarly preceded subsequent VA [aHR = 2.96 (1.59-5.50), P = .0008]. Both were independently associated with all-cause mortality, with a numerically higher aHR for HF events [aHR = 7.96 (4.71-13.47), P < .0001] than for VA [aHR = 4.43 (2.35-8.36), P < .0001]. Sensitivity analyses suggested that the VA-HF association was strongest for shock-treated arrhythmias. In exploratory analyses, VA was strongly associated with subsequent HF events in subcutaneous ICD recipients [aHR = 15.08 (4.62-49.22), P < .0001] but not in transvenous ICD recipients (P for interaction = .0002). CONCLUSION: In ICD recipients with persistent LV dysfunction following MI, VA and HF events are bidirectionally associated and independently associated with mortality. The VA-HF association was strongest for shock-treated arrhythmias. These findings highlight the potential value of integrated HF and VA management.

Auteurs: Mathieu Echivard, Jean-Marc Sellal, John J V McMurray, Chloé Ziliox, Luca Monzo, Zohra Lamiral, Kévin Duarte, Christian De Chillou, Guillaume Baudry, Nicolas Girerd

---
Bron: European journal of heart failure, https://doi.org/10.1093/ejhf/xuag312. Bijgewerkt 2026-11-07T02:48:34Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.